Alix-Panabieres, C. & Pantel, K. Challenges in circulating tumour cell research. Nat. Rev. Cancer 14, 623–631 (2014).
Nagrath, S. et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235–1239 (2007).
Yoon, H. J. et al. Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat. Nanotechnol. 8, 735–741 (2013).
Zhao, W. et al. Bioinspired multivalent DNA network for capture and release of cells. Proc. Natl Acad. Sci. USA 109, 19626–19631 (2012).
Stott, S. L. et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc. Natl Acad. Sci. USA 107, 18392–18397 (2010).
Ozkumur, E. et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci. Transl. Med. 5, 179ra147 (2013).
Lee, A. et al. All-in-one centrifugal microfluidic device for size-selective circulating tumor cell isolation with high purity. Anal. Chem. 86, 11349–11356 (2014).
Kim, T. H. et al. FAST: size-selective, clog-free isolation of rare cancer cells from whole blood at a liquid–liquid interface. Anal. Chem. 89, 1155–1162 (2017).
Adams, A. A. et al. Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics with an integrated conductivity sensor. J. Am. Chem. Soc. 130, 8633–8641 (2008).
Zhang, Y., Zhou, L. & Qin, L. High-throughput 3D cell invasion chip enables accurate cancer metastatic assays. J. Am. Chem. Soc. 136, 15257–15262 (2014).
Zhang, Y., Zhang, W. & Qin, L. Mesenchymal-mode migration assay and antimetastatic drug screening with high-throughput microfluidic channel networks. Angew. Chem. Int. Ed. 53, 2344–2348 (2014).
Toriello, N. M. et al. Integrated microfluidic bioprocessor for single-cell gene expression analysis. Proc. Natl Acad. Sci. USA 105, 20173–20178 (2008).
Reyes, E. E. et al. Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J. Transl. Med. 12, 313 (2014).
Ciaccio, M. F., Wagner, J. P., Chuu, C. P., Lauffenburger, D. A. & Jones, R. B. Systems analysis of EGF receptor signaling dynamics with microwestern arrays. Nat. Methods 7, 148–155 (2010).
Rimm, D. L. What brown cannot do for you. Nat. Biotechnol. 24, 914–916 (2006).
Liu, Y. et al. Modulation of fluorescent protein chromophores to detect protein aggregation with turn-on fluorescence. J. Am. Chem. Soc. 140, 7381–7384 (2018).
Pollock, S. B. et al. Highly multiplexed and quantitative cell-surface protein profiling using genetically barcoded antibodies. Proc. Natl Acad. Sci. USA 115, 2836–2841 (2018).
Engelen, W., Meijer, L. H., Somers, B., de Greef, T. F. & Merkx, M. Antibody-controlled actuation of DNA-based molecular circuits. Nat. Commun. 8, 14473 (2017).
Fan, R. et al. Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood. Nat. Biotechnol. 26, 1373–1378 (2008).
Nam, J. M., Thaxton, C. S. & Mirkin, C. A. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 301, 1884–1886 (2003).
Angelo, M. et al. Multiplexed ion beam imaging of human breast tumors. Nat. Med. 20, 436–442 (2014).
Rissin, D. M. et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28, 595–599 (2010).
de la Rica, R. & Stevens, M. M. Plasmonic ELISA for the ultrasensitive detection of disease biomarkers with the naked eye. Nat. Nanotechnol. 7, 821–824 (2012).
Xue, M. et al. Chemical methods for the simultaneous quantitation of metabolites and proteins from single cells. J. Am. Chem. Soc. 137, 4066–4069 (2015).
Gerdtsson, T. et al. Multiplex protein detection on circulating tumor cells from liquid biopsies using imaging mass cytometry. Converg. Sci. Phys. Oncol. 4, 015002 (2018).
Hughes, A. J. et al. Single-cell western blotting. Nat. Methods 11, 749–755 (2014).
Sinkala, E. et al. Profiling protein expression in circulating tumour cells using microfluidic western blotting. Nat. Commun. 8, 14622 (2017).
Poudineh, M. et al. Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic ranking. Nat. Nanotechnol. 12, 274–281 (2017).
Labib, M. et al. Single-cell mRNA cytometry via sequence-specific nanoparticle clustering and trapping. Nat. Chem. 10, 489–495 (2018).
Herold, S., Herkert, B. & Eilers, M. Facilitating replication under stress: an oncogenic function of MYC? Nat. Rev. Cancer 9, 441–444 (2009).
Dang, C. V. MYC on the path to cancer. Cell 149, 22–35 (2012).
Beaulieu, M. E. et al. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy. Sci. Transl. Med. 11, eaar5012 (2019).
Burke, A. J., Ali, H., O’Connell, E., Sullivan, F. J. & Glynn, S. A. Sensitivity profiles of human prostate cancer cell lines to an 80 kinase inhibitor panel. Anticancer Res. 36, 633–641 (2016).
Lakshman, M. et al. Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res. 68, 2024–2032 (2008).
Thiery, J. P. Epithelial–mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442–454 (2002).
Lindsay, C. R. et al. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer. BMC Cancer 16, 168 (2016).
Ray Chaudhuri, A. & Nussenzweig, A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat. Rev. Mol. Cell Biol. 18, 610–621 (2017).
Schiewer, M. J. et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2, 1134–1149 (2012).
Kosaka, T. et al. The prognostic significance of OCT4 expression in patients with prostate cancer. Hum. Pathol. 51, 1–8 (2016).
Salem, A. F., Whitaker-Menezes, D., Howell, A., Sotgia, F. & Lisanti, M. P. Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance. Cell Cycle 11, 4174–4180 (2012).
Gao, L. et al. Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS ONE 8, e63563 (2013).
Wu, M. et al. Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression. Proteomics 7, 1973–1983 (2007).
Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719–724 (2009).
Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787–790 (2009).
Scher, H. I. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375, 1437–1446 (2010).
Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701–711 (2015).
Sinkevicius, K. W. et al. Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis. Proc. Natl Acad. Sci. USA 111, 10299–10304 (2014).
Chen, Y. & Chi, P. Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. J. Hematol. Oncol. 11, 78–78 (2018).
Wylie, A. A. et al. The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1. Nature 543, 733–737 (2017).
Holderfield, M., Deuker, M. M., McCormick, F. & McMahon, M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat. Rev. Cancer 14, 455–467 (2014).
Hauschild, A. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358–365 (2012).
Rebbeck, T. R. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346, 1616–1622 (2002).
Jeyasekharan, A. D. et al. A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization. Nat. Struct. Mol. Biol. 20, 1191–1198 (2013).
Eriksson, I., Wettermark, B. & Bergfeldt, K. Real-world use and outcomes of olaparib: a population-based cohort study. Target. Oncol. 13, 725–733 (2018).
Mateo, J. et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697–1708 (2015).
Rowe, B. P. & Glazer, P. M. Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. Breast Cancer Res. 12, 203 (2010).
Green, B. J. et al. Isolation of phenotypically distinct cancer cells using nanoparticle-mediated sorting. ACS Appl. Mater. Interfaces 9, 20435–20443 (2017).